Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2018 Nov 21. pii: S0924-8579(18)30332-7. doi: 10.1016/j.ijantimicag.2018.11.007. [Epub ahead of print]

2.

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-nonsusceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2018 Oct 25. pii: S0924-8579(18)30299-1. doi: 10.1016/j.ijantimicag.2018.10.007. [Epub ahead of print]

3.

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00592-18. doi: 10.1128/AAC.00592-18. Print 2018 Dec.

PMID:
30249690
4.

Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:140-147. doi: 10.1016/j.jgar.2018.07.012. Epub 2018 Jul 30.

PMID:
30071354
5.

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781. doi: 10.1093/jac/dky267.

PMID:
30010951
6.

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788. doi: 10.1093/jac/dky266.

PMID:
30010894
7.

Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:12-19. doi: 10.1016/j.jgar.2018.05.017. Epub 2018 May 29.

PMID:
29857057
8.

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.

Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00169-18. doi: 10.1128/AAC.00169-18. Print 2018 Jul.

PMID:
29760135
9.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02569-17. doi: 10.1128/AAC.02569-17. Print 2018 Jul.

PMID:
29760124
10.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
11.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Apr 11. doi: 10.1093/jac/dky107. [Epub ahead of print]

PMID:
29659861
12.

Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program.

Wise MG, Estabrook MA, Sahm DF, Stone GG, Kazmierczak KM.

PLoS One. 2018 Apr 2;13(4):e0195281. doi: 10.1371/journal.pone.0195281. eCollection 2018.

13.

Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases.

Wise MG, Horvath E, Young K, Sahm DF, Kazmierczak KM.

J Med Microbiol. 2018 Mar;67(3):289-295. doi: 10.1099/jmm.0.000691. Epub 2018 Feb 5.

PMID:
29458684
14.

Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.

Hackel MA, Iaconis JP, Karlowsky JA, Sahm DF.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01892-17. doi: 10.1128/JCM.01892-17. Print 2018 Apr.

15.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01968-17. doi: 10.1128/AAC.01968-17. Print 2018 Feb.

16.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17. doi: 10.1128/AAC.01904-17. Print 2018 Jan.

17.

In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

Karlowsky JA, Hackel MA, Bouchillon SK, Alder J, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):151-157. doi: 10.1016/j.diagmicrobio.2017.07.001. Epub 2017 Jul 8.

PMID:
28793964
18.

Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide.

Hackel MA, Karlowsky JA, Dressel D, Sahm DF.

J Clin Microbiol. 2017 Oct;55(10):3021-3027. doi: 10.1128/JCM.00972-17. Epub 2017 Jul 26.

19.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00472-17. doi: 10.1128/AAC.00472-17. Print 2017 Sep.

20.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00093-17. doi: 10.1128/AAC.00093-17. Print 2017 Sep.

21.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

Braz J Infect Dis. 2017 May - Jun;21(3):343-348. doi: 10.1016/j.bjid.2017.03.006. Epub 2017 Apr 8.

22.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02209-16. doi: 10.1128/AAC.02209-16. Print 2017 Jun.

23.

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014.

Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF.

J Clin Microbiol. 2017 Jun;55(6):1638-1649. doi: 10.1128/JCM.02316-16. Epub 2017 Mar 15.

24.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
25.

Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

J Med Microbiol. 2017 Jan;66(1):61-69. doi: 10.1099/jmm.0.000421. Epub 2017 Feb 22.

PMID:
28051952
26.

In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study.

Huang DB, Hawser S, Gemmell CG, Sahm DF.

Can J Infect Dis Med Microbiol. 2017;2017:3948626. doi: 10.1155/2017/3948626. Epub 2017 Dec 17.

27.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W; SOLO I, SOLO II Investigators.

Int J Antimicrob Agents. 2016 Nov;48(5):528-534. doi: 10.1016/j.ijantimicag.2016.07.019. Epub 2016 Sep 13.

PMID:
27665522
28.

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.

Biedenbach DJ, Bouchillon SK, Johnson B, Alder J, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2016 Dec;35(12):1933-1939. Epub 2016 Sep 27.

PMID:
27677280
29.

Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.

Bartsch SM, Huang SS, Wong KF, Slayton RB, McKinnell JA, Sahm DF, Kazmierczak K, Mueller LE, Jernigan JA, Lee BY.

J Clin Microbiol. 2016 Nov;54(11):2757-2762. Epub 2016 Aug 31.

30.
31.

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Oct;86(2):194-9. doi: 10.1016/j.diagmicrobio.2016.07.012. Epub 2016 Jul 14.

PMID:
27461798
32.

Discrepancy between genotypic and phenotypic extended-spectrum β-lactamase rates in Escherichia coli from intra-abdominal infections in the USA.

Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF.

J Med Microbiol. 2016 Sep;65(9):905-9. doi: 10.1099/jmm.0.000307. Epub 2016 Jul 8.

PMID:
27392786
33.

Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014.

Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Aug;85(4):459-65. doi: 10.1016/j.diagmicrobio.2016.04.022. Epub 2016 May 6.

PMID:
27306116
34.

Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).

Zalacain M, Biedenbach DJ, Badal RE, Young K, Motyl M, Sahm DF.

Clin Ther. 2016 Jun;38(6):1510-1521. doi: 10.1016/j.clinthera.2016.04.035. Epub 2016 May 24.

PMID:
27234360
35.

In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).

Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9. doi: 10.1128/AAC.00220-16. Print 2016 Aug.

36.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.

37.

Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii.

Lob SH, Hoban DJ, Sahm DF, Badal RE.

Int J Antimicrob Agents. 2016 Apr;47(4):317-23. doi: 10.1016/j.ijantimicag.2016.01.015. Epub 2016 Mar 5.

PMID:
27020541
38.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.

39.

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2849-57. doi: 10.1128/AAC.02286-15. Print 2016 May.

40.

Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014.

Lob SH, Badal RE, Hackel MA, Sahm DF.

J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):72-79. doi: 10.1093/jpids/piv109.

PMID:
26883618
41.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15.

42.

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.

Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1385-92. doi: 10.1128/AAC.01870-15.

43.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.

Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1067-78. doi: 10.1128/AAC.02379-15. Print 2016 Feb.

44.

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.

Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.

Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.

PMID:
26541881
45.

In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF.

J Antimicrob Chemother. 2016 Jan;71(1):162-9. doi: 10.1093/jac/dkv311. Epub 2015 Oct 26.

PMID:
26503667
46.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.

47.

Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.

Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW.

JAMA Ophthalmol. 2015 Dec;133(12):1445-54. doi: 10.1001/jamaophthalmol.2015.3888.

PMID:
26502312
48.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7. doi: 10.1128/AAC.01833-15. Epub 2015 Sep 28.

49.

Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013.

Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF.

J Glob Antimicrob Resist. 2015 Sep;3(3):190-197. doi: 10.1016/j.jgar.2015.05.005. Epub 2015 Jul 6.

PMID:
27873708
50.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.

Supplemental Content

Support Center